Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') cytotoxicity

Pharmacogenetics and Genomics

Volumn 16, Issue 11, 2006, Pages 789-799

  Carmo, Helena ^a   Brulport, Marc ^c   Hermes, Matthias ^c   Oesch, Franz ^f   Silva, Renata ^a   Ferreira, Luísa M ^b   Branco, Paula S ^b   Boer, Douwe De ^g   Remião, Fernando ^a   Carvalho, Félix ^a   Schön, Michael R ^c   Krebsfaenger, Niels ^d   Doehmer, Johannes ^e   Bastos, Maria De Lourdes ^a   Hengstler, Jan G ^c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d Schwarz Pharma AG   (Germany)

^e GenPharmTox BioTech AG   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

3,4 methylenedioxymethamphetamine; CYP2D6; Ecstasy toxicity; Metabolism; Polymorphism

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE DERIVATIVE; ISOENZYME; N METHYL ALPHA METHYLDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DNA POLYMORPHISM; DRUG SENSITIVITY; ELECTROCHEMISTRY; ENZYME ACTIVITY; GENETIC TRANSFECTION; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL;

ALLELES; ANIMALS; CATALYSIS; CELL LINE; CRICETINAE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEOXYEPINEPHRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; MODELS, BIOLOGICAL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXIDATION-REDUCTION; POLYMORPHISM, GENETIC;

EID: 33750289167     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000230419.05221.fc     Document Type: Article

References (77)

1. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 2003; 55:463-508.
2. de la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, Pichini S. Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. Clin Pharmacokinet 2004;43:157-185.
3. de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 2004; 26:137-144.
4. Parrott AC. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 2001; 16:557-577.
5. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-Methylenedioxymethamphetamine ('ecstasy'). Lancet 1992; 340:384-387.
6. Brauer RB, Heidecke CD, Nathrath W, Beckurts KT, Vorwald P, Zilker TR, et al. Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. Transpl Int 1997; 10:229-233.
7. Greene SL, Dargan PI, O'connor N, Jones AL, Kerins M. Multiple toxicity from 3,4-methylenedioxymethamphetamine ('ecstasy'). Am J Emerg Med 2003; 21:121-124.
8. Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther 1999; 13:129-133.
9. Schwab M, Seyringer E, Brauer RB, Hellinger A, Griese EU. Fatal MDMA intoxication. Lancet 1999; 353:593-594.
10. Colado MI, O'Shea E, Granados R, Murray TK, Green AR. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 1997; 121:889-900.
11. Colado MI, Williams JL, Green AR. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 1995; 115:1281-1289.
12. Gollamudi R, Ali SF, Lipe G, Newport G, Webb P, Lopez M, et al. Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. Neurotoxicology 1989; 10:455-466.
13. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA ('Ecstasy') on brain serotonin neurons in human beings. Lancet 1998; 352:1433-1437.
14. McCann UD, Eligulashvili V, Ricaurte GA. (± )3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 2000; 42:11-16.
15. Morgan MJ. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 2000; 152:230-248.
16. Schifano F. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology 2004; 173:242-248.
17. Green AR. MDMA: fact and fallacy, and the need to increase knowledge in both the scientific and popular press. Psychopharmacology 2004; 173:231-233.
18. de Letter EA, Bouche MP, Bocxlaer JFV, Lambert WE, Piette MH. Interpretation of a 3,4-methylenedioxymethamphetamine (MDMA) blood level: discussion by means of a distribution study in two fatalities. Forensic Sci Int 2004; 141:85-90.
19. O'Donohoe A, O'Flynn K, Shields K, Hawi Z, Gill M. MDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6. Addict Biol 1998; 3:309-314.
20. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 2000; 112-113:133-142.
21. Lim HK, Foltz RL. Identification of metabolites of 3,4-(methylenedioxy) methamphetamine in human urine. Chem Res Toxicol 1989; 2:142-143.
22. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, et al. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 2000; 49:104-109.
23. Johnson M, Letter AA, Merchant K, Hanson GR, Gibb JW. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. J Pharmacol Exp Ther 1988; 244:977-982.
24. Maurer HH. On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatographymass spectrometry. Ther Drug Monit 1996; 18:465-470.
25. Zhao ZY, Castagnoli NJ, Ricaurte GA, Steele T, Martello M. Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)methamphetamine]. Chem Res Toxicol 1992; 5:89-94.
26. Lim HK, Foltz RL. In vivo formation of aromatic hydroxylated metabolites of 3,4-(methylenedioxy)methamphetamine in the rat: identification by ion trap tandem mass spectrometric (MS/MS and MS/MS/MS) techniques. Biol Mass Spectrom 1991; 20:677-686.
27. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, et al. The demethylenation of methylenedioxymethamphetamine ('ecstasy') by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994; 47:1151-1156.
28. Ramamoorthy Y, Yu A, Suh N, Haining RL, Tyndale RF, Sellers EM. Reduced (±)-3,4-methylenedioxymethamphetamine ('Ecstasy') metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 2002; 63:2111-2119.
29. Kreth K, Kovar K, Schwab M, Zanger UM. Identification of the human cytochromes P450 involved in the oxidative metabolism of 'Ecstasy'-related designer drugs. Biochem Pharmacol 2000; 59:1563-1571.
30. Capela JP, Meisel A, Abreu AR, Branco PS, Ferreira LM, Lobo AM, et al. Neurotoxicity of ecstasy metabolites in rat cortical neurons, and influence of hyperthermia. J Pharmacol Exp Ther 2006; 316:53-61.
31. Easton N, Fry J, O'Shea E, Watkins A, Kingston S, Marsden CA. Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy). Brain Res 2003; 987:144-154.
32. Jones DC, Duvauchelle C, Ikegami A, Olsen CM, Lau SS, de la Torre R, et al. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther 2005; 313:422-431.
33. Carvalho M, Milhazes N, Remiao F, Borges F, Fernandes E, Amado F, et al. Hepatotoxicity of 3,4-methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Arch Toxicol 2004; 78:16-24.
34. Carvalho M, Remiao F, Milhazes N, Borges F, Fernandes E, Carvalho F, et al. The toxicity of N-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology 2004; 200:193-203.
35. Carvalho M, Remiao F, Milhazes N, Borges F, Fernandes E, Monteiro M, et al. Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chem Res Toxicol 2004; 17:623-632.
36. Carvalho M, Hawksworth G, Milhazes N, Borges F, Monks TJ, Fernandes E, et al. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch Toxicol 2002; 76:581-588.
37. Hartung TK, Schofield E, Short AI, Parr MJ, Henry JA. Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion. Q J Med 2002; 95:431-437.
38. Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, et al. The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 2002; 135:649-656.
39. Escobedo I, O'Shea E, Orio L, Sanchez V, Segura M, de la Torre R, et al. A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. Br J Pharmacol 2005; 144:231-241.
40. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:23-37.
41. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53:111-122.
42. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5:6-13.
43. de la Torre R, Farre M, Mathuna BO, Roset PN, Pizarro N, Segura M, et al. MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur J Clin Pharmacol 2005; 61:551-554.
44. Krebsfaenger N, Murdter TE, Zanger UM, Eichelbaum MF, Doehmer J. V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humans. ALTEX 2003; 20:143-154.
45. Soares ME, Carvalho M, Carmo H, Remiao F, Carvalho F, Bastos ML. Simultaneous determination of amphetamine derivatives in human urine after SPE extraction and HPLC-UV analysis. Biomed Chromatogr 2004; 18:125-131.
46. Carmo H, de Boer D, Remiao F, Carvalho F, Reys LA, Bastos ML. Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration. J Chromatogr B Anal Technol Biomed Life Sci 2004; 811:143-152.
47. Carmo H, de Boer D, Remião F, Carvalho F, Reys LA, Bastos ML. Identification of 4-methylthioamphetamine and some of its metabolites in mouse urine by GC-MS after acute administration. J Anal Toxicol 2002; 26:228-232.
48. Kumagai Y, Lin LY, Schmitz DA, Cho AK. Hydroxyl radical mediated demethylenation of (methylenedioxy)phenyl compounds. Chem Res Toxicol 1991; 4:330-334.
49. Carmo H, Hengstler JG, de Boer D, Ringel M, Carvalho F, Fernandes E, et al. Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:198-205.
50. Carmo H, Hengstler JG, de Boer D, Ringel M, Remiao F, Carvalho F, et al. Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology 2005; 206:75-89.
51. Coecke S, Bogni A, Langezaal I, Worth A, Hartung T, Monshouwer M. The use of genetically engineered cells for assessing CYP2D6-related polymorphic effects. Toxicol In Vitro 2001; 15:553-556.
52. Doehmer J, Buters JT, Luch A, Soballa V, Baird WM, Morisson H, et al. Molecular studies on the toxifying effects by genetically engineered cytochromes P450. Drug Metab Rev 1999; 31:423-435.
53. Philip PA, Ali-Sadat S, Doehmer J, Kocarek T, Akhtar A, Lu H, et al. Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs. Cancer Chemother Pharmacol 1999; 43:59-67.
54. Bogni A, Monshouwer M, Moscone A, Hidestrand M, Ingelman-Sundberg M, Hartung T, et al. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. Toxicol In Vitro 2005; 19:621-629.
55. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290:136-145.
56. Farré M, de la Torre R, Mathuna BO, Roset PN, Peiró AM, Torrens M, et al. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology 2004; 173:364-375.
57. Bindoli A, Rigobello MP, Deeble DJ. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic Biol Med 1992; 13:391-405.
58. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ. Role of quinones in toxicology. Chem Res Toxicol 2000; 13:135-160.
59. Hiramatsu M, Kumagai Y, Unger SE, Cho AK. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 1990; 254:521-527.
60. Monks TJ, Jones DC, Bai F, Lau SS. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther Drug Monit 2004; 26:132-136.
61. Bindoli A, Rigobello MP, Galzigna L. Toxicity of aminochromes. Toxicol Lett 1989; 48:3-20.
62. Zhang F, Dryhurst G. Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J Med Chem 1994; 37:1084-1098.
63. Remiao F, Carvalho M, Carmo H, Carvalho F, Bastos ML. Cu2+-induced isoproterenol oxidation into isoprenochrome in adult rat calcium-tolerant cardiomyocytes. Chem Res Toxicol 2002; 15:861-869.
64. Remiao F, Carmo H, Carvalho F, Bastos ML. Inhibition of Glutathione Reductase by Isoproterenol Oxidation Products. J Enzyme Inhib 1999; 15:47-61.
65. Lin LY, Kumagai Y, Cho AK. Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. Chem Res Toxicol 1992; 5:401-406.
66. Ramamoorthy Y, Tyndale RF, Sellers EM. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 2001; 11:477-487.
67. Gilhooly TC, Daly AK. CYP2D6 deficiency, a factor in ecstasy related deaths? Br J Clin Pharmacol 2002; 54:69-70.
68. Simantov R, Tauber M. The abused drug MDMA (Ecstasy) induces programmed death of human serotonergic cells. FASEB J 1997; 11:141-146.
69. Stumm G, Schlegel J, Schafer T, Wurz C, Mennel HD, Krieg JC, et al. Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. FASEB J 1999; 13:1065-1072.
70. de Letter EA, Piette MH, Lambert WE, Cordonnier JA. Amphetamines as potential inducers of fatalities:a review in the district of Ghent from 1976-2004. Med Sci Law 2006; 46:37-65.
71. Garcia-Repetto R, Moreno E, Soriano T, Jurado C, Gimenez MP, Menendez M. Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose. Forensic Sci Int 2003; 135:110-114.
72. de Letter EA, Clauwaert KM, Lambert WE, Bocxlaer JFV, DeLeenheer AP, Piette MH. Distribution study of 3,4-methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine in a fatal overdose. J Anal Toxicol 2002; 26:113-118.
73. Sticht G, Pluisch F, Bierhoff E, Kaferstein H. Fatal outcome of Ecstasy overdose. Arch Kriminol 2003; 211:73-80.
74. Segura M, Ortuno J, Farre M, McLure JA, Pujadas M, Pizarro N, et al. 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4- methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 2001; 14:1203-1208.
75. Zhu BT. Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 2002; 3:321-349.
76. Nagata K, Yamazoe Y. Pharmacogenetics of sulfotransferase. Annu Rev Pharmacol Toxicol 2000; 40:159-176.
77. Freimuth RR, Eckloff B, Wieben ED, Weinshilboum RM. Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies. Pharmacogenetics 2001; 11:747-756.